European Journal of Cancer
Volume 39, Issue 9 , Pages 1302-1309 , June 2003

The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines

Received 30 August 2002 ,Revised 14 October 2002 ,Accepted 26 November 2002.

References 

  1. Murphy LJ. Growth factors and steroid hormone action in endometrial cancer. J. Steroid. Biochem. Mol. Biol. 1994;48:419–423
  2. Fujimoto J, Hori M, Ichigo S, Misao R, Tamaya T. Preliminary study of oncogene expressions in endometrial cancers. Eur. J. Gynaecol. Oncol. 1995;16:40–47
  3. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer. 1995;76(10 Suppl):2034–2040
  4. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 1999;18:138–143
  5. Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW. Mutations and amplification of oncogenes in endometrial cancer. Oncology. 1999;56:59–65
  6. Baselga J, Tripathy D, Mendelsohn J, et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 1999;4(Suppl. 12):78–83
  7. Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin. Cancer Res. 1999;5:2877–2883
  8. Migliaccio A, Di Domenico M, Castoria G, et al.  Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996;15:1292–1300
  9. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. USA. 1999;96:4686–4691
  10. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 1972;15:1012–1019
  11. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai-Zasshi 1985, 37, 1103–1111.
  12. Janes PW, Daly RJ, de Fazio A, Sutherland RL. Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 1994;9:3691–3698
  13. Charest DL, Mordret G, Harder KW, Jirik F, Pelech SL. Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1. Mol. Cell. Biol. 1993;13:4679–4690
  14. Kumar R, Mandal M, Vadlamudi R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin. Oncol. 2000;26(6 Suppl. 11):84–91
  15. Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor, human breast epithelial cell invasion. Cancer Res. 2001;61:400–405
  16. Hijazi MM, Thompson EW, Tang C, et al.  Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int. J. Oncol. 2000;17:629–641
  17. Hamburger AW, Yoo JY. Phosphatidylinositol 3-kinase mediates heregulin-induced growth inhibition in human epithelial cells. Anticancer Res. 1997;17:2197–2200
  18. Wallasch C, Weiss FU, Niederfellner G, et al.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995;4:4267–4275
  19. O'Hagan RC, Hassell JA. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene. 1998;16:301–310
  20. Lupu R, Cardillo C, Cho C, et al.  The significance of heregulin in breast cancer tumor progression and drug resistance. Br. Cancer Res. Treat. 1996;38:57–66
  21. Krane IM, Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene. 1996;12:1781–1788
  22. Aguilar Z, Akita RW, Finn RS, et al.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene. 1999;18:6050–6062
  23. Kunisue H, Kurebayashi J, Otsuki T, et al.  Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br. J. Cancer. 2000;82:46–51
  24. Fujimoto J, Hori M, Ichigo S, Morishita S, Tamaya T. Estrogen activates migration potential of endometrial cancer cells through basement membrane. Tumour Biol. 1996;17:48–57
  25. Talukder AH, Jorgensen HF, Mandal M, et al.  Regulation of elongation factor-1alpha expression by growth factors and anti-receptor blocking antibodies. J. Biol. Chem. 2001;276:5636–5642
  26. Lewis GD, Lofgren JA, McMurtrey AE, et al.  Growth regulation of human breast and ovarian tumor cells by heregulin, evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 1996;56:1457–1465
  27. Collins P, Webb C. Estrogen hits the surface. Nature Med. 1999;5:1130–1131
  28. Filardo EJ, Quinn JA, Bland KI, et al.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000;14:1649–1660
  29. Filardo EJ, Quinn JA, Frackelton AR, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30, stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 2002;16:70–84
  30. Wade CB, Robinson S, Shapiro RA, Dorsa DM. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology. 2001;142:2336–2342

PII: S0959-8049(02)00777-3

doi: 10.1016/S0959-8049(02)00777-3

European Journal of Cancer
Volume 39, Issue 9 , Pages 1302-1309 , June 2003

Article Tools

* Image Usage & Resolution